Related Experiment Video
Updated: Mar 4, 2026
Measurement of Total Calcium in Neurons by Electron Probe X-ray Microanalysis
Published on: November 20, 2013
MCC-135 Exerts Antiepileptic and Neuroprotective Effects by Downregulating NCX1 Expression to Decrease Intracellular
Chaoning Liu1, Min He1, Rida Li1
1Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
Background:
Approximately 30% of epilepsy patients still develop drug resistance after standard antiepileptic treatment. Therefore, there is an urgent need to identify new drug targets to improve seizure control. Previous studies have shown that NCX1 can regulate the intracellular Ca2+ levels in astrocytes and neurons, which are closely associated with epilepsy. MCC-135 has shown potential as an antiseizure medication due to its ability to downregulate NCX and reduce intracellular calcium overload; however, its role and mechanism in epilepsy remain unclear.
Methods:
This study employed single-cell analysis and molecular docking to identify the potential molecular targets of MCC-135 in treating epilepsy. Additionally, we used a KA-induced epileptic mouse model to validate these molecular levels and the therapeutic effects and mechanisms of MCC-135.
Results:
Relative to controls, NCX1 expression was significantly upregulated in the hippocampus of KA-induced epileptic mice. Immunofluorescence staining revealed that NCX1 was co-localized with both astrocytes and neurons. MCC-135 treatment significantly prolonged the seizure latency in KA-induced epileptic mice and alleviated hippocampal neuronal damage. Furthermore, MCC-135 effectively reduced NCX1 expression, alleviated intracellular calcium overload, and downregulated glutamate levels in the epileptic mice.
Conclusion:
MCC-135 exerts neuroprotective and antiepileptic effects by downregulating NCX1 expression, thereby alleviating calcium overload and reducing glutamate levels in the hippocampus. We are the first to propose the role and mechanism of MCC-135 in epilepsy treatment, providing novel insights into its potential as a therapeutic agent for epilepsy.
Insights
The drug MCC-135 shows promise for treating epilepsy by reducing NCX1 expression, which lowers calcium overload and glutamate levels in the brain. This study reveals MCC-135
Area of Science:
- Neuroscience
- Pharmacology
- Epilepsy Research
Background:
- Epilepsy affects 30% of patients resistant to standard treatments, necessitating new therapeutic targets.
- Intracellular calcium dysregulation in astrocytes and neurons is linked to epilepsy.
- MCC-135's antiseizure potential is noted, but its mechanism in epilepsy is unknown.
Purpose of the Study:
- To identify MCC-135's molecular targets for epilepsy treatment using computational and experimental methods.
- To validate MCC-135's therapeutic effects and mechanisms in an epilepsy mouse model.
Main Methods:
- Single-cell analysis and molecular docking were used to identify MCC-135 targets.
- A kainic acid (KA)-induced epileptic mouse model was employed for validation.
- Immunofluorescence staining assessed NCX1 co-localization in astrocytes and neurons.
Main Results:
- NCX1 expression was upregulated in the hippocampus of KA-induced epileptic mice.
- MCC-135 treatment increased seizure latency and reduced hippocampal damage.
- MCC-135 decreased NCX1 expression, calcium overload, and glutamate levels.
Conclusions:
- MCC-135 demonstrates neuroprotective and antiseizure effects by downregulating NCX1.
- The drug alleviates hippocampal calcium overload and glutamate levels.
- This study is the first to elucidate MCC-135's mechanism in epilepsy, offering new therapeutic insights.
Related Concept Videos
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
01:14Antiepileptic Drugs: Glutamate Antagonists
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...